How Small Biotechs Should Protect Their Interests During Mergers and Acquisitions - Early-stage companies need to assess whether a potential deal might unduly encumber the value of their intellectual

ADVERTISEMENT

How Small Biotechs Should Protect Their Interests During Mergers and Acquisitions
Early-stage companies need to assess whether a potential deal might unduly encumber the value of their intellectual property


BioPharm International
Volume 21, Issue 1

Q: How can a company best navigate the complexities of all the tactical options—strategic partnering, collaborations, licensing, another financing round and M&A?

A: Clearly understanding the financial risks and benefits of all options is the first step. However, other factors must be considered—how much control is the company willing to cede? What decision-making responsibilities are most important to the company and the long-term success of the drug or technology? What areas of expertise does the company have and where is it lacking?

Today's deal-making environment offers many options for life sciences companies. Companies need to fully understand the options—and the risks and rewards—related to strategic alliances and M&A so they can make the best decisions to preserve long-term enterprise value and also to enhance the probability of success.

Sergio Garcia is co chair of the life sciences group, and partner, corporate and intellectual property group, at Fenwick & West LLP, San Francisco, CA, 415.875.2366,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here